Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag)

Michael E J Buhl, Torgny Sunnerhagen, Olivier Join-Lambert, Trefor Morris, Samo Jeverica, Marc V Assous, Nurver U Toprak, Luis Alcalá-Hernandez, Reto Lienhard, Alida C M Veloo, Hugo Cruz, József Sóki, Anita Novak, Annarita Mazzariol, Ingrid Wybo, Yann Dumont, Ulrik S Justesen, ReSuBacfrag Study Group, Barbara Juliane Holzknecht (Medlem af forfattergruppering)

Abstract

OBJECTIVES: Bacteroides fragilis is the most frequent cause of anaerobic bacteraemia. Although recent data suggest a rise in antimicrobial resistance (AMR) of this and other anaerobic bacteria, surveillance remains limited due to a lack of both data availability and comparability. However, a newly introduced standardised method for antimicrobial susceptibility testing (AST) of anaerobic bacteria has made larger scale surveillance possible for the first time. The aim of this study was to investigate phenotypic AMR of Bacteroides fragilis isolates from bacteraemia across Europe in 2022.

METHODS: In a multicentre approach, clinical microbiology laboratories in Europe were invited to contribute results of AST for Bacteroides fragilis blood culture isolates (including only the first isolate per patient and year). AST of a selection of four antibiotics was performed locally by participating laboratories in a prospective or retrospective manner, using the new EUCAST disc diffusion method on fastidious anaerobe agar (FAA-HB).

RESULTS: A total of 16 European countries reported antimicrobial susceptibilities in 449 unique isolates of Bacteroides fragilis from blood cultures in 2022. Clindamycin demonstrated the highest resistance rates (20.9%, range 0 - 63.6%), followed by piperacillin-tazobactam (11.1%, 0-54.5%), meropenem (13.4%, 0-45.5%), and metronidazole (1.8%, 0-20.0%), all with wide variation between countries.

CONCLUSION: Considering that the mean resistance rates across Europe were higher than expected for three of the four anti-anaerobic antibiotics under surveillance, both local AST of clinically relevant isolates of Bacteroides fragilis and continued surveillance on an international level is warranted.

OriginalsprogEngelsk
Artikelnummer107241
TidsskriftInternational Journal of Antimicrobial Agents
Vol/bind64
Udgave nummer3
Sider (fra-til)107241
ISSN0924-8579
DOI
StatusUdgivet - sep. 2024

Fingeraftryk

Dyk ned i forskningsemnerne om 'Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag)'. Sammen danner de et unikt fingeraftryk.

Citationsformater